Source
Patsnap
Transthyretin amyloidosis is driving intensive pharmaceutical IP activity across four mechanistically distinct modalities — RNAi silencing, small-molecule stabilization, antibody immunotherapy, and CRISPR gene editing. This analysis maps the patent landscape, identifies the dominant assignees, and highlights combination strategies emerging as the next frontier in ATTR treatment.
News Url